466 related articles for article (PubMed ID: 19635559)
1. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
[TBL] [Abstract][Full Text] [Related]
2. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
3. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.
Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L
Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
6. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow transplantation from a pediatric donor with a high frequency of cytomegalovirus-specific T-cells.
Komatsu H; Kogawa K; Nonoyama S; Inui A; Sogo T; Fujisawa T; Klenerman P
J Med Virol; 2006 Dec; 78(12):1616-23. PubMed ID: 17063516
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
10. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
11. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
12. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
[TBL] [Abstract][Full Text] [Related]
13. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.
Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; Garcia-Noblejas A; Clari MA; Chilet M; López J; Hernández-Boluda JC; Remigia MJ; Navarro D
J Med Virol; 2010 Jul; 82(7):1208-15. PubMed ID: 20513086
[TBL] [Abstract][Full Text] [Related]
15. Rapid generation of CMV pp65-specific T cells for immunotherapy.
Bao L; Sun Q; Lucas KG
J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants.
Gibson L; Dooley S; Trzmielina S; Somasundaran M; Fisher D; Revello MG; Luzuriaga K
J Infect Dis; 2007 Jun; 195(12):1789-98. PubMed ID: 17492595
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
20. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
